ReviewCancer reports (Hoboken, N.J.)2026
Gut Microbiota: A Potential Role in Modulating Carcinogenesis and Response to Anti-Cancer Therapies.
Review in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe effects of microbiota on cancer are not only limited to their role in oncogenesis, progression and response to anticancer therapies; the disease itself is also influenced by microbiota. In recent investigations, alterations in the gut bacterial community between cancer patients and healthy individuals have been reported. Outcomes targeted to gut microbiota composition, microbial metabolites, immune responses, and other pertinent measures are also aggregated and elaborated in this review. RECENT
findingsNumerous preclinical and clinical experiments have explored the use of gut microbiota as a new research avenue with encouraging outcomes in enhancing treatment efficacy and mitigating side effects related to treatment. The pathophysiology of cancer cells and modulation by microbiomes via many signaling pathways could be useful in determining the role of microbiota in developing novel therapeutic approaches and possible targets for cancer treatment.
conclusionThough different bacterial species can cause various clinical outcomes, more research is still required to identify more precise and profound underlying mechanisms in the relationship between gut microbiota and anticancer therapy. This could lead to improved patient outcomes overall and more focused clinical applications down the road.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.